Represents growth of 32% at the midpoint compared to expected 2024 revenue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) Expects Weight-Loss Pill Approval in 2026
- Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
- Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
- Verve Therapeutics announces anticipated 2025 milestones
- Potential acquisition of Scorpion positive for Relay, says Barclays